Evidence map›Paper›PMID 39019010›Full record

ArticleCell reports. Medicine2024

Development of a hydrogen peroxide-inactivated vaccine that protects against viscerotropic yellow fever in a non-human primate model.

Ian J Amanna, Archana Thomas, Flora Engelmann, Erika Hammarlund, Hans-Peter Raué, Adam L Bailey, Elizabeth A Poore, Benjamin K Quintel, Anne D Lewis, Michael K Axthelm and 5 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cell reports. Medicine, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Review
  2. Article
  3. Review
  4. Review
  5. Article
  6. Review
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Ian J AmannaNajít Technologies, Inc., Beaverton, OR 97006, USA.
Archana ThomasDivision of Neuroscience, Oregon National Primate Research Center, Oregon Health & Science University, Beaverton, OR 97006, USA.
Flora EngelmannDepartment of Microbiology, Immunology and Molecular Genetics, University of Kentucky, College of Medicine, Lexington, KY 40506, USA.
Erika HammarlundDivision of Neuroscience, Oregon National Primate Research Center, Oregon Health & Science University, Beaverton, OR 97006, USA.
Hans-Peter RauéDivision of Neuroscience, Oregon National Primate Research Center, Oregon Health & Science University, Beaverton, OR 97006, USA.
Adam L BaileyDepartment of Pathology & Laboratory Medicine, University of Wisconsin - Madison, Madison, WI 53706, USA.
Elizabeth A PooreNajít Technologies, Inc., Beaverton, OR 97006, USA.
Benjamin K QuintelNajít Technologies, Inc., Beaverton, OR 97006, USA.
Anne D LewisDivision of Comparative Medicine, Oregon National Primate Research Center, Oregon Health & Science University, Beaverton, OR 97006, USA.
Michael K AxthelmDivision of Pathobiology & Immunology, Oregon National Primate Research Center, and The Vaccine & Gene Therapy Institute, Oregon Health & Science University, Beaverton, OR 97006, USA.
Amanda L JohnsonDivision of Comparative Medicine, Oregon National Primate Research Center, Oregon Health & Science University, Beaverton, OR 97006, USA.
Lois M A ColginDivision of Comparative Medicine, Oregon National Primate Research Center, Oregon Health & Science University, Beaverton, OR 97006, USA.
Michael S DiamondDepartments of Medicine, Molecular Microbiology, Pathology & Immunology, Washington University School of Medicine, St. Louis, MO 63110, USA.
Ilhem MessaoudiDepartment of Microbiology, Immunology and Molecular Genetics, University of Kentucky, College of Medicine, Lexington, KY 40506, USA.
Mark K SlifkaDivision of Neuroscience, Oregon National Primate Research Center, Oregon Health & Science University, Beaverton, OR 97006, USA. Electronic address: slifkam@ohsu.edu.

Funding

Upgrade of confocal microscopy at the Oregon National Primate Research CenterP51OD011092 · OD · OREGON HEALTH & SCIENCE UNIVERSITY · PI Bonnie J. Nagel · 2012 to 2026
$203.9M
The Burden of Chikungunya and Dengue Infection in KenyaU54AI081680 · NIAID · OREGON HEALTH & SCIENCE UNIVERSITY · PI NELSON, JAY A · 2009 to 2013
$40.4M
Antibody-based Protection against FlavivirsesR01AI073755 · NIAID · WASHINGTON UNIVERSITY · PI DIAMOND, MICHAEL S, FREMONT, DAVED H. · 2007 to 2022
$11.4M
Development of a Yellow Fever Vaccine for Vulnerable PopulationR44AI079898 · NIAID · NAJIT TECHNOLOGIES, INC. · PI AMANNA, IAN JAMES, SLIFKA, MARK K · 2011 to 2020
$6.2M
Determinants of yellow fever pathogenesis in humansDP5OD029608 · OD · UNIVERSITY OF WISCONSIN-MADISON · PI BAILEY, ADAM LEE · 2020 to 2024
$1.9M
NIAID NIH HHS R01 AI073755NIAID NIH HHS R44 AI079898NIAID NIH HHS U54 AI081680NIH HHS DP5 OD029608NIH HHS P51 OD011092
6 · The paper itself

Abstract

Yellow fever virus (YFV) is endemic in >40 countries and causes viscerotropic disease with up to 20%-60% mortality. Successful live-attenuated yellow fever (YF) vaccines were developed in the mid-1930s, but their use is restricted or formally contraindicated in vulnerable populations including infants, the elderly, and people with compromised immune systems. In these studies, we describe the development of a next-generation hydrogen peroxide-inactivated YF vaccine and determine immune correlates of protection based on log neutralizing index (LNI) and neutralizing titer-50% (NT

Indexed as

Antibodies, NeutralizingAntibodies, ViralDisease Models, AnimalHydrogen PeroxideMacaca mulattaVaccines, InactivatedYellow FeverYellow Fever VaccineYellow fever virusAnimalsChlorocebus aethiopsHumansVaccines, AttenuatedVero CellsAntibodies, NeutralizingAntibodies, ViralHydrogen PeroxideVaccines, AttenuatedVaccines, InactivatedYellow Fever Vaccinecorrelate of protectionflavivirusesimmunological memoryLNIneutralizing antibodiesNT(50)rhesus macaquesvaccinationyellow fever

Identifiers

PMID39019010
PMCPMC11293362

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.